MAP Pharmaceuticals develops and plans to commercialize new drugs for children and adults who suffer from diseases that we believe are not treated adequately by currently available medicine. We expect to initiate two Phase 3 clinical programs by early 2008 with product candidates to treat pediatric asthma and migraine headache.
MAP Pharmaceuticals is developing a proprietary nebulized version of budesonide for pediatric asthma
MAP Pharmaceuticals is developing a proprietary inhaled treatment for migraine headache
Proprietary aerosol delivery and pharmacological profiling technology